Dr. John S Shenk, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 3605 Mayfair Ave, Hibbing, MN 55746 Phone: 218-262-3441 Fax: 218-362-6989 |
Dr. William Charles Vincent, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 3605 Mayfair Ave, Hibbing, MN 55746 Phone: 218-262-3441 Fax: 218-362-6907 |
Sandra Lea Hanson, Surgery Medicare: Medicare Enrolled Practice Location: 3605 Mayfair Ave, Hibbing, MN 55746 Phone: 218-262-3441 |
Dakota A Orvedal, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 750 E 34th St, Hibbing, MN 55746 Phone: 218-722-3700 |
Laura Marie Stoiber, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 3605 Mayfair Ave, Hibbing, MN 55746 Phone: 218-262-3441 |
News Archive
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
Women with gout are at greater risk of a heart attack than men with the disease, indicates research published ahead of print in the Annals of the Rheumatic Diseases.
Mortality of patients with severe acute pancreatitis (SAP) approaches 30%-40%. An imbalance between the early systemic inflammatory response syndrome (SIRS), and the later compensatory counter-inflammatory response, and development of multiple organ failure (MOF) are considered to be the primary causes of morbidity and mortality in SAP. Excessive leukocyte activation (including neutrophils and monocyte-macrophage lineage) with cytokinemia play a critical role in the pathogenesis of pancreatitis and even more so, of the subsequent inflammatory response.
Computerworld: The digital divide is alive and well when it comes to health care technology. Although President Barack Obama has made it a priority to have medical facilities deploy electronic health records (EHR) over the next four years, the people most likely to benefit - those in poor and minority communities - are unlikely to see them anytime soon.
› Verified 5 days ago